Sefunda, as Swiss based company, established in early 2019, has a small, dedicated team of professionals with background in IVD product development, molecular epidemiology, medtech and material science combined with business acumen. We develop a near patient / point of care diagnostics platform that includes antibiotic resistance testing especially for indications that are on the edge of becoming untreatable. Educated estimates assume that in todays world only 2% of the total healthcare costs are applied to diagnostics. On the other hand 60% – 70% of medical decisions are based on proper diagnosis. Our point of care platform will significantly contribute to better and timely diagnosis. Sefunda is funded by seed investors.